Search Medical Condition
Please enter condition
Please choose location from dropdown

Risskov, Denmark Clinical Trials

A listing of Risskov, Denmark clinical trials actively recruiting patients volunteers.

RESULTS

Found (281) clinical trials

Cognitive Behavioral Therapy for Treatment of Insomnia in Patients With Major Depression

Participants are included from GPs in Aarhus. Initial assessment is carried out through a personal interview with the participants who are screened with Hamilton Depression Rating Scale, MINI (Mini International Neuropsychiatric Interview) and instructed to fill out an ISI-form (Insomnia Severity Index (Morin, 1993)), DBAS-16, Dysfunctional Beliefs and Attitudes about ...

Phase N/A

0.86 miles

Learn More »

Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

In the current study, the investigators aim to investigate the effect of additional treatment with prednisolone on symptomatic improvement, global functioning, cognition and on immunological parameters in patients with early-stage psychotic disorder, applying a randomized double-blind placebo-controlled add-on design. A placebo-controlled design was chosen in order to differentiate between clinical ...

Phase

0.86 miles

Learn More »

the Antidepressant Effect of rTMS as add-on to ECT

ECT is a well-established and effective method for the treatment of severe depression. During the last decades, rTMS has appeared as a potential new non-invasive antidepressant method, which may be a potential alternative to ECT due to fewer side effects. Both methods expose the brain to an electric current. But ...

Phase N/A

0.86 miles

Learn More »

CBT for Anxiety Disorder in Children With Co-morbid ASD

The primary objective is to investigate the effect of a manualised Cognitive Behavioural Therapy (CBT) programme The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD) for anxiety disorder adapted to children with Autism Spectrum Disorder (ASD) in a waitlist controlled design. The investigators will investigate treatment effects ...

Phase N/A

0.86 miles

Learn More »

Rehabilitation to Patients Over 65 Years Undergoing THA

Fase 1: 600 patients waiting for or already having received total hip-/knee-replacement participated in a questionnaire study using SF- 36. The aim was to document self-rated health among this population. Fase 2: Results from the cross section study form the base for the RCT, where 160 patients over 65 years ...

Phase

1.6 miles

Learn More »

A Registry for Patients With Chronic Hypoparathyroidism

This is a prospective, observational disease and drug registry designed to evaluate the safety and effectiveness profile of rhPTH(1-84) under conditions of routine clinical practice and to observe the clinical course of chronic hypoparathyrodism. No treatment is provided as a result of participating in this registry and all decisions on ...

Phase N/A

1.66 miles

Learn More »

High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)

In this protocol the term high-risk neuroblastoma refers to children with either disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age of one or INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene Between 10% and 20% of children with stage ...

Phase

1.93 miles

Learn More »

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

Complement 5a and its receptor C5aR (CD88) are involved in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. This is a randomized, double-blind, active-controlled Phase 3 study to evaluate the safety and efficacy of the orally-administered, selective C5aR inhibitor CCX168 (avacopan) in inducing and sustaining remission in patients with anti-neutrophil ...

Phase

1.96 miles

Learn More »

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Participants with FLT3/ITD AML in first morphologic complete remission (CR1) undergoing allogeneic hematopoietic stem cell transplant (HCT) will be randomized to receive gilteritinib or placebo 30 to 90 days after HCT for a two year period. Participants will be stratified according to: 1) conditioning regimen intensity (myeloablative vs. reduced intensity/non-myeloablative), ...

Phase

1.96 miles

Learn More »

Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs

Multicenter, randomized, open-label, parallel-group study of guadecitabine vs Treatment Choice (TC). Approximately 408 subjects will be randomly assigned 2:1 to either guadecitabine or TC. Guadecitabine: approximately 272 subjects. TC: approximately 136 subjects. Before randomization, the investigator will assign each subject to one of the following TC options Low dose cytarabine ...

Phase

1.96 miles

Learn More »